Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-06-01

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?

NCT00312403

Glaucoma

COMPLETED NA

Long Term Evaluation of Primary Congenital Glaucoma Management in Sohag University Hospital

NCT04949555

Primary Congenital Glaucoma

UNKNOWN

Correlation Between Optical Coherence Tomography Angiography and Photopic Negative Response in Patients With Glaucoma

NCT05104294

Open Angle Glaucoma

COMPLETED

Visual Field Changes and OCT Angiographic Chorioretinal Changes in Patients With Primary Open Angle Glaucoma

NCT06978101

Visual Field OCT Angiography Chorioretinal Changes +1 more

COMPLETED

Gene Polymorphisms of Corticosteroid-induced Ocular Hypertension

NCT03250819

Corticosteroid Induced Ocular Hypertension/Glaucoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual ﬁeld, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place

POAG is the most common type of glaucoma that is characterized by speciﬁc glaucomatous retinal, optic nerve, and clinical ﬁndings without a clear secondary cause.

POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual ﬁeld in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP).

Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.

The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outﬂow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor.

Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma (POAG)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Normal healthy volunteers aged \> 30 years

genotyping assay by polymerase chain reaction

Intervention Type GENETIC

Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.

Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

Experimental Group

Patients aged \>30 years and diagnosed with Primary Open Angle Glaucoma

genotyping assay by polymerase chain reaction

Intervention Type GENETIC

Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.

Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

genotyping assay by polymerase chain reaction

Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.

Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women older than 30 years
* Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
* Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)